Serum YKL-40 predicts relapse-free and overall survival in patients with american joint committee on cancer stage I and II melanoma
- Author
- SCHMIDT, Henrik; JOHANSEN, Julia S; SJOEGREN, Pia; CHRISTENSEN, Ib J; SORENSEN, Boe S; FODE, Kirsten; LARSEN, Jorn; VON DER MAASE, Hans
[1] Departments of Oncology, Plastic Surgery, and Clinical Biochemistry, Aarhus University Hospital, Depart ment of Rheumatology, Herlev University Hospital, Herlev, Denmark
[2] Department of Surgical Gastroenterology, Hvidovre University Hospital, Hvidovre, Denmark - Source
Journal of clinical oncology. 2006, Vol 24, Num 5, pp 798-804, 7 p ; ref : 53 ref
- ISSN
- 0732-183X
- Scientific domain
- Medical oncology
- Publisher
- Lippincott Williams & Wilkins, Baltimore, MD
- Publication country
- United States
- Document type
- Article
- Language
- English
- Keyword (fr)
- Cancérologie Glycoprotéine Homme Marqueur biologique Mélanome malin Pronostic Protéine sécrétée Stade précoce Sérum Protéine YKL40 Survie sans récidive Peau pathologie Tumeur maligne
- Keyword (en)
- Cancerology Glycoprotein Human Biological marker Malignant melanoma Prognosis Secretory protein Early stage Serum YKL40 protein Relapse free survival Skin disease Malignant tumor
- Keyword (es)
- Cancerología Glicoproteína Hombre Marcador biológico Melanoma maligno Pronóstico Proteína segregada Estadio precoz Suero Proteína YKL40 Supervivencia sin recidiva Piel patología Tumor maligno
- Classification
- Pascal
- 002 Biological and medical sciences / 002B Medical sciences / 002B08 Dermatology / 002B08A Tumors of the skin and soft tissue. Premalignant lesions
- Discipline
- Dermatology Tumours
- Origin
- Inist-CNRS
- Database
- PASCAL
- INIST identifier
- 17500977
Sauf mention contraire ci-dessus, le contenu de cette notice bibliographique peut être utilisé dans le cadre d’une licence CC BY 4.0 Inist-CNRS / Unless otherwise stated above, the content of this bibliographic record may be used under a CC BY 4.0 licence by Inist-CNRS / A menos que se haya señalado antes, el contenido de este registro bibliográfico puede ser utilizado al amparo de una licencia CC BY 4.0 Inist-CNRS
Access to the document
Install on your browser
DOI
10.1200/JCO.2005.03.7960 
https://dx.doi.org/10.1200/JCO.2005.03.7960
"O:13:\"PanistOpenUrl\":36:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000idc\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:24:\"10.1200\/JCO.2005.03.7960\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:131:\"Serum YKL-40 predicts relapse-free and overall survival in patients with american joint committee on cancer stage I and II melanoma\";s:9:\"\u0000*\u0000jtitle\";s:28:\"Journal of clinical oncology\";s:9:\"\u0000*\u0000stitle\";s:14:\"J. clin. oncol\";s:7:\"\u0000*\u0000date\";s:4:\"2006\";s:9:\"\u0000*\u0000volume\";s:2:\"24\";s:8:\"\u0000*\u0000issue\";s:1:\"5\";s:8:\"\u0000*\u0000spage\";s:3:\"798\";s:8:\"\u0000*\u0000epage\";s:3:\"804\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0732-183X\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:7:\"SCHMIDT\";s:10:\"\u0000*\u0000aufirst\";s:6:\"Henrik\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:7:{i:0;s:17:\"JOHANSEN, Julia S\";i:1;s:13:\"SJOEGREN, Pia\";i:2;s:17:\"CHRISTENSEN, Ib J\";i:3;s:15:\"SORENSEN, Boe S\";i:4;s:13:\"FODE, Kirsten\";i:5;s:12:\"LARSEN, Jorn\";i:6;s:19:\"VON DER MAASE, Hans\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:0:\"\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:131:\"Serum YKL-40 predicts relapse-free and overall survival in patients with american joint committee on cancer stage I and II melanoma\";s:8:\"\u0000*\u0000place\";s:13:\"Baltimore, MD\";s:6:\"\u0000*\u0000pub\";s:29:\"Lippincott Williams & Wilkins\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:1:\"7\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Panist access
"O:12:\"IstexOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:24:\"10.1200\/JCO.2005.03.7960\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:131:\"Serum YKL-40 predicts relapse-free and overall survival in patients with american joint committee on cancer stage I and II melanoma\";s:9:\"\u0000*\u0000jtitle\";s:28:\"Journal of clinical oncology\";s:9:\"\u0000*\u0000stitle\";s:14:\"J. clin. oncol\";s:7:\"\u0000*\u0000date\";s:4:\"2006\";s:9:\"\u0000*\u0000volume\";s:2:\"24\";s:8:\"\u0000*\u0000issue\";s:1:\"5\";s:8:\"\u0000*\u0000spage\";s:3:\"798\";s:8:\"\u0000*\u0000epage\";s:3:\"804\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0732-183X\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:7:\"SCHMIDT\";s:10:\"\u0000*\u0000aufirst\";s:6:\"Henrik\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:7:{i:0;s:17:\"JOHANSEN, Julia S\";i:1;s:13:\"SJOEGREN, Pia\";i:2;s:17:\"CHRISTENSEN, Ib J\";i:3;s:15:\"SORENSEN, Boe S\";i:4;s:13:\"FODE, Kirsten\";i:5;s:12:\"LARSEN, Jorn\";i:6;s:19:\"VON DER MAASE, Hans\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:0:\"\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:131:\"Serum YKL-40 predicts relapse-free and overall survival in patients with american joint committee on cancer stage I and II melanoma\";s:8:\"\u0000*\u0000place\";s:13:\"Baltimore, MD\";s:6:\"\u0000*\u0000pub\";s:29:\"Lippincott Williams & Wilkins\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:1:\"7\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Istex access
"O:16:\"UnpaywallOpenUrl\":35:{s:8:\"\u0000*\u0000email\";s:27:\"assistance-portail@inist.fr\";s:6:\"\u0000*\u0000fmt\";N;s:6:\"\u0000*\u0000doi\";s:24:\"10.1200\/JCO.2005.03.7960\";s:6:\"\u0000*\u0000pii\";N;s:7:\"\u0000*\u0000pmid\";N;s:9:\"\u0000*\u0000atitle\";N;s:9:\"\u0000*\u0000jtitle\";N;s:9:\"\u0000*\u0000stitle\";N;s:7:\"\u0000*\u0000date\";N;s:9:\"\u0000*\u0000volume\";N;s:8:\"\u0000*\u0000issue\";N;s:8:\"\u0000*\u0000spage\";N;s:8:\"\u0000*\u0000epage\";N;s:8:\"\u0000*\u0000pages\";N;s:7:\"\u0000*\u0000issn\";N;s:8:\"\u0000*\u0000eissn\";N;s:9:\"\u0000*\u0000aulast\";N;s:10:\"\u0000*\u0000aufirst\";N;s:9:\"\u0000*\u0000auinit\";N;s:10:\"\u0000*\u0000auinitm\";N;s:5:\"\u0000*\u0000au\";N;s:9:\"\u0000*\u0000aucorp\";N;s:7:\"\u0000*\u0000isbn\";N;s:8:\"\u0000*\u0000coden\";N;s:8:\"\u0000*\u0000genre\";N;s:7:\"\u0000*\u0000part\";N;s:9:\"\u0000*\u0000btitle\";N;s:8:\"\u0000*\u0000title\";N;s:8:\"\u0000*\u0000place\";N;s:6:\"\u0000*\u0000pub\";N;s:10:\"\u0000*\u0000edition\";N;s:9:\"\u0000*\u0000tpages\";N;s:9:\"\u0000*\u0000series\";N;s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";N;}"
Unpaywall access
"O:16:\"EuropePMCOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:24:\"10.1200\/JCO.2005.03.7960\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:131:\"Serum YKL-40 predicts relapse-free and overall survival in patients with american joint committee on cancer stage I and II melanoma\";s:9:\"\u0000*\u0000jtitle\";s:28:\"Journal of clinical oncology\";s:9:\"\u0000*\u0000stitle\";s:14:\"J. clin. oncol\";s:7:\"\u0000*\u0000date\";s:4:\"2006\";s:9:\"\u0000*\u0000volume\";s:2:\"24\";s:8:\"\u0000*\u0000issue\";s:1:\"5\";s:8:\"\u0000*\u0000spage\";s:3:\"798\";s:8:\"\u0000*\u0000epage\";s:3:\"804\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0732-183X\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:7:\"SCHMIDT\";s:10:\"\u0000*\u0000aufirst\";s:6:\"Henrik\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:7:{i:0;s:17:\"JOHANSEN, Julia S\";i:1;s:13:\"SJOEGREN, Pia\";i:2;s:17:\"CHRISTENSEN, Ib J\";i:3;s:15:\"SORENSEN, Boe S\";i:4;s:13:\"FODE, Kirsten\";i:5;s:12:\"LARSEN, Jorn\";i:6;s:19:\"VON DER MAASE, Hans\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:0:\"\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:131:\"Serum YKL-40 predicts relapse-free and overall survival in patients with american joint committee on cancer stage I and II melanoma\";s:8:\"\u0000*\u0000place\";s:13:\"Baltimore, MD\";s:6:\"\u0000*\u0000pub\";s:29:\"Lippincott Williams & Wilkins\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:1:\"7\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Europe PubMed Central access
"O:11:\"BaseOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:24:\"10.1200\/JCO.2005.03.7960\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:131:\"Serum YKL-40 predicts relapse-free and overall survival in patients with american joint committee on cancer stage I and II melanoma\";s:9:\"\u0000*\u0000jtitle\";s:28:\"Journal of clinical oncology\";s:9:\"\u0000*\u0000stitle\";s:14:\"J. clin. oncol\";s:7:\"\u0000*\u0000date\";s:4:\"2006\";s:9:\"\u0000*\u0000volume\";s:2:\"24\";s:8:\"\u0000*\u0000issue\";s:1:\"5\";s:8:\"\u0000*\u0000spage\";s:3:\"798\";s:8:\"\u0000*\u0000epage\";s:3:\"804\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0732-183X\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:7:\"SCHMIDT\";s:10:\"\u0000*\u0000aufirst\";s:6:\"Henrik\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:7:{i:0;s:17:\"JOHANSEN, Julia S\";i:1;s:13:\"SJOEGREN, Pia\";i:2;s:17:\"CHRISTENSEN, Ib J\";i:3;s:15:\"SORENSEN, Boe S\";i:4;s:13:\"FODE, Kirsten\";i:5;s:12:\"LARSEN, Jorn\";i:6;s:19:\"VON DER MAASE, Hans\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:0:\"\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:131:\"Serum YKL-40 predicts relapse-free and overall survival in patients with american joint committee on cancer stage I and II melanoma\";s:8:\"\u0000*\u0000place\";s:13:\"Baltimore, MD\";s:6:\"\u0000*\u0000pub\";s:29:\"Lippincott Williams & Wilkins\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:1:\"7\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Base Search access
"O:12:\"ArXivOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:24:\"10.1200\/JCO.2005.03.7960\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:131:\"Serum YKL-40 predicts relapse-free and overall survival in patients with american joint committee on cancer stage I and II melanoma\";s:9:\"\u0000*\u0000jtitle\";s:28:\"Journal of clinical oncology\";s:9:\"\u0000*\u0000stitle\";s:14:\"J. clin. oncol\";s:7:\"\u0000*\u0000date\";s:4:\"2006\";s:9:\"\u0000*\u0000volume\";s:2:\"24\";s:8:\"\u0000*\u0000issue\";s:1:\"5\";s:8:\"\u0000*\u0000spage\";s:3:\"798\";s:8:\"\u0000*\u0000epage\";s:3:\"804\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0732-183X\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:7:\"SCHMIDT\";s:10:\"\u0000*\u0000aufirst\";s:6:\"Henrik\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:7:{i:0;s:17:\"JOHANSEN, Julia S\";i:1;s:13:\"SJOEGREN, Pia\";i:2;s:17:\"CHRISTENSEN, Ib J\";i:3;s:15:\"SORENSEN, Boe S\";i:4;s:13:\"FODE, Kirsten\";i:5;s:12:\"LARSEN, Jorn\";i:6;s:19:\"VON DER MAASE, Hans\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:0:\"\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:131:\"Serum YKL-40 predicts relapse-free and overall survival in patients with american joint committee on cancer stage I and II melanoma\";s:8:\"\u0000*\u0000place\";s:13:\"Baltimore, MD\";s:6:\"\u0000*\u0000pub\";s:29:\"Lippincott Williams & Wilkins\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:1:\"7\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
arXiv access
